[go: up one dir, main page]

MX2022015524A - Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. - Google Patents

Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.

Info

Publication number
MX2022015524A
MX2022015524A MX2022015524A MX2022015524A MX2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A
Authority
MX
Mexico
Prior art keywords
cyclohexyl
crystalline forms
ylsulfanyl
ureido
thiazol
Prior art date
Application number
MX2022015524A
Other languages
English (en)
Inventor
Jing Teng
Yizheng Cao
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2022015524A publication Critical patent/MX2022015524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente descripción se refiere a a) formas cristalinas de ácido {2-[3-ciclohexil-3-(trans-4- propoxi-ciclohexil)-ureido]-tia zol-5-ilsulfanil}-acético ("Compuesto I "); b) composiciones farmacéuticas, que comprenden una o más formas cristalinas del Compuesto I y, opcionalmente, un portador farmacéuticamente aceptable; c) métodos para tratar un tipo de diabetes mellitus u otros trastornos mediante la administración de una o más formas cristalinas del Compuesto I; y d) métodos para la preparación de formas cristalinas del Compuesto I.
MX2022015524A 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. MX2022015524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035994P 2020-06-08 2020-06-08
PCT/US2021/036082 WO2021252309A1 (en) 2020-06-08 2021-06-07 Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof

Publications (1)

Publication Number Publication Date
MX2022015524A true MX2022015524A (es) 2023-03-22

Family

ID=78846441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015524A MX2022015524A (es) 2020-06-08 2021-06-07 Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.

Country Status (9)

Country Link
US (1) US20230219910A1 (es)
EP (1) EP4161639A4 (es)
JP (1) JP2023530785A (es)
KR (1) KR20230048501A (es)
CN (1) CN116056760A (es)
AU (1) AU2021289591A1 (es)
CA (1) CA3181665A1 (es)
MX (1) MX2022015524A (es)
WO (1) WO2021252309A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964197B1 (en) * 2013-03-04 2020-03-25 vTv Therapeutics LLC Solid compositions comprising a glucokinase activator and methods of making and using the same
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834840B2 (ja) * 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
AU2011258460B2 (en) * 2010-05-26 2015-02-19 Vtv Therapeutics Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
CN118453592A (zh) * 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
EP2964197B1 (en) * 2013-03-04 2020-03-25 vTv Therapeutics LLC Solid compositions comprising a glucokinase activator and methods of making and using the same
CA2903433A1 (en) * 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
US11266630B2 (en) * 2016-12-15 2022-03-08 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor

Also Published As

Publication number Publication date
WO2021252309A1 (en) 2021-12-16
EP4161639A4 (en) 2024-01-17
KR20230048501A (ko) 2023-04-11
JP2023530785A (ja) 2023-07-19
CA3181665A1 (en) 2021-12-16
AU2021289591A1 (en) 2023-01-19
EP4161639A1 (en) 2023-04-12
CN116056760A (zh) 2023-05-02
US20230219910A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
BRPI0409109A (pt) novos compostos
WO2003002593A3 (en) Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
NO20074012L (no) 1-tio-D-glucitolderivater
ATE416159T1 (de) Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
BRPI0316908B8 (pt) preparo de suspensões aquosas estéreis incluindo ingredientes ativos cristalinos micronizados para inalação
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2023002547A (es) Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos.
EP3134393B1 (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
WO2020236690A9 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
NZ778907A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
WO2021076938A8 (en) Tropolone derivatives and tautomers thereof for iron regulation in animals
ZA202309001B (en) Abhd6 antagonist
IL42787A (en) Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids
WO2023150790A3 (en) Novel and highly selective sars-cov-2 mpro inhibitors
EP1500656B1 (en) Biguanide derivatives and their use as antidiabetic drugs
RU2008112310A (ru) Соединение тиоморфолина и способ его получения